Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Feb;59(2):156–159. doi: 10.1038/bjc.1989.33

Germ cell tumour chemotherapy.

A Horwich 1
PMCID: PMC2246990  PMID: 2539172

Full text

PDF
156

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bajorin D., Katz A., Chan E., Geller N., Vogelzang N., Bosl G. J. Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies. J Clin Oncol. 1988 May;6(5):786–792. doi: 10.1200/JCO.1988.6.5.786. [DOI] [PubMed] [Google Scholar]
  2. Birch R., Williams S., Cone A., Einhorn L., Roark P., Turner S., Greco F. A. Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol. 1986 Mar;4(3):400–407. doi: 10.1200/JCO.1986.4.3.400. [DOI] [PubMed] [Google Scholar]
  3. Bosl G. J., Geller N. L., Bajorin D., Leitner S. P., Yagoda A., Golbey R. B., Scher H., Vogelzang N. J., Auman J., Carey R. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol. 1988 Aug;6(8):1231–1238. doi: 10.1200/JCO.1988.6.8.1231. [DOI] [PubMed] [Google Scholar]
  4. Bosl G. J., Geller N. L., Cirrincione C., Vogelzang N. J., Kennedy B. J., Whitmore W. F., Jr, Vugrin D., Scher H., Nisselbaum J., Golbey R. B. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res. 1983 Jul;43(7):3403–3407. [PubMed] [Google Scholar]
  5. Bosl G. J., Geller N. L., Vogelzang N. J., Carey R., Auman J., Whitmore W. F., Herr H., Morse M., Sogani P., Chan E. Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors. J Clin Oncol. 1987 Mar;5(3):436–440. doi: 10.1200/JCO.1987.5.3.436. [DOI] [PubMed] [Google Scholar]
  6. Calvert A. H., Harland S. J., Newell D. R., Siddik Z. H., Harrap K. R. Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev. 1985 Sep;12 (Suppl A):51–57. doi: 10.1016/0305-7372(85)90018-0. [DOI] [PubMed] [Google Scholar]
  7. Crawford S. M., Newlands E. S., Begent R. H., Rustin G. J., Bagshawe K. D. The effect of intensity of administered treatment on the outcome of germ cell tumours treated with POMB/ACE chemotherapy. Br J Cancer. 1989 Feb;59(2):243–246. doi: 10.1038/bjc.1989.49. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cullen M. H., Harper P. G., Woodroffe C. M., Kirkbride P., Clarke J. Chemotherapy for poor risk germ cell tumours. An independent evaluation of the POMB/ACE regime. Br J Urol. 1988 Nov;62(5):454–460. doi: 10.1111/j.1464-410x.1988.tb04396.x. [DOI] [PubMed] [Google Scholar]
  9. Daugaard G., Rossing N., Rørth M. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol. 1988;21(2):163–167. doi: 10.1007/BF00257365. [DOI] [PubMed] [Google Scholar]
  10. Daugaard G., Rŗth M. High-dose cisplatin and VP-16 with bleomycin, in the management of advanced metastatic germ cell tumors. Eur J Cancer Clin Oncol. 1986 Apr;22(4):477–485. doi: 10.1016/0277-5379(86)90115-x. [DOI] [PubMed] [Google Scholar]
  11. Donohue J. P., Roth L. M., Zachary J. M., Rowland R. G., Einhorn L. H., Williams S. G. Cytoreductive surgery for metastatic testis cancer: tissue analysis of retroperitoneal masses after chemotherapy. J Urol. 1982 Jun;127(6):1111–1114. doi: 10.1016/s0022-5347(17)54256-1. [DOI] [PubMed] [Google Scholar]
  12. Einhorn L. H. Have new aggressive chemotherapy regimens improved results in advanced germ cell tumors? Eur J Cancer Clin Oncol. 1986 Nov;22(11):1289–1293. doi: 10.1016/0277-5379(86)90135-5. [DOI] [PubMed] [Google Scholar]
  13. Einhorn L. H., Williams S. D. Chemotherapy of disseminated testicular cancer. A random prospective study. Cancer. 1980 Sep 15;46(6):1339–1344. doi: 10.1002/1097-0142(19800915)46:6<1339::aid-cncr2820460607>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  14. Einhorn L. H., Williams S. D., Troner M., Birch R., Greco F. A. The role of maintenance therapy in disseminated testicular cancer. N Engl J Med. 1981 Sep 24;305(13):727–731. doi: 10.1056/NEJM198109243051303. [DOI] [PubMed] [Google Scholar]
  15. Hendry W. F., Goldstraw P., Peckham M. J. The role of surgery in the combined management of metastases from malignant teratomas of testis. Br J Urol. 1987 Apr;59(4):358–358. doi: 10.1111/j.1464-410x.1987.tb04649.x. [DOI] [PubMed] [Google Scholar]
  16. Hitchins R. N., Newlands E. S., Smith D. B., Begent R. H., Rustin G. J., Bagshawe K. D. Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis. Br J Cancer. 1989 Feb;59(2):236–242. doi: 10.1038/bjc.1989.48. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Logothetis C. J., Samuels M. L., Selig D. E., Ogden S., Dexeus F., Swanson D., Johnson D., von Eschenbach A. Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients. Am J Med. 1986 Aug;81(2):219–228. doi: 10.1016/0002-9343(86)90255-x. [DOI] [PubMed] [Google Scholar]
  18. Logothetis C. J., Samuels M. L., Selig D., Swanson D., Johnson D. E., von Eschenbach A. C. Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis. J Clin Oncol. 1985 Mar;3(3):326–335. doi: 10.1200/JCO.1985.3.3.326. [DOI] [PubMed] [Google Scholar]
  19. Mulder P. O., de Vries E. G., Koops H. S., Splinter T., Maas A., van der Geest S., Mulder N. H., Sleijfer D. T. Chemotherapy with maximally tolerable doses of VP 16-213 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors. Eur J Cancer Clin Oncol. 1988 Apr;24(4):675–679. doi: 10.1016/0277-5379(88)90298-2. [DOI] [PubMed] [Google Scholar]
  20. Newlands E. S., Bagshawe K. D., Begent R. H., Rustin G. J., Crawford S. M., Holden L. Current optimum management of anaplastic germ cell tumours of the testis and other sites. Br J Urol. 1986 Jun;58(3):307–314. doi: 10.1111/j.1464-410x.1986.tb09061.x. [DOI] [PubMed] [Google Scholar]
  21. Ozols R. F., Corden B. J., Jacob J., Wesley M. N., Ostchega Y., Young R. C. High-dose cisplatin in hypertonic saline. Ann Intern Med. 1984 Jan;100(1):19–24. doi: 10.7326/0003-4819-100-1-19. [DOI] [PubMed] [Google Scholar]
  22. Ozols R. F., Ihde D. C., Linehan W. M., Jacob J., Ostchega Y., Young R. C. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol. 1988 Jun;6(6):1031–1040. doi: 10.1200/JCO.1988.6.6.1031. [DOI] [PubMed] [Google Scholar]
  23. Peckham M. J., Barrett A., Liew K. H., Horwich A., Robinson B., Dobbs H. J., McElwain T. J., Hendry W. F. The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP). Br J Cancer. 1983 May;47(5):613–619. doi: 10.1038/bjc.1983.99. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Peckham M. J., Horwich A., Blackmore C., Hendry W. F. Etoposide and cisplatin with or without bleomycin as first-line chemotherapy for patients with small-volume metastases of testicular nonseminoma. Cancer Treat Rep. 1985 May;69(5):483–488. [PubMed] [Google Scholar]
  25. Peckham M. J., Horwich A., Easton D. F., Hendry W. F. The management of advanced testicular teratoma. Br J Urol. 1988 Jul;62(1):63–68. doi: 10.1111/j.1464-410x.1988.tb04268.x. [DOI] [PubMed] [Google Scholar]
  26. Pizzocaro G., Piva L., Salvioni R., Zanoni F., Milani A. Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer. Cancer. 1985 Nov 15;56(10):2411–2415. doi: 10.1002/1097-0142(19851115)56:10<2411::aid-cncr2820561012>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  27. Roth B. J., Greist A., Kubilis P. S., Williams S. D., Einhorn L. H. Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. J Clin Oncol. 1988 Aug;6(8):1239–1247. doi: 10.1200/JCO.1988.6.8.1239. [DOI] [PubMed] [Google Scholar]
  28. Samson M. K., Rivkin S. E., Jones S. E., Costanzi J. J., LoBuglio A. F., Stephens R. L., Gehan E. A., Cummings G. D. Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group study. Cancer. 1984 Mar 1;53(5):1029–1035. doi: 10.1002/1097-0142(19840301)53:5<1029::aid-cncr2820530503>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  29. Stoter G., Sylvester R., Sleijfer D. T., ten Bokkel Huinink W. W., Kaye S. B., Jones W. G., van Oosterom A. T., Vendrik C. P., Spaander P., de Pauw M. Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III Study. Cancer Res. 1987 May 15;47(10):2714–2718. [PubMed] [Google Scholar]
  30. Watson J. V., Stewart J., Evan G. I., Ritson A., Sikora K. The clinical significance of flow cytometric c-myc oncoprotein quantitation in testicular cancer. Br J Cancer. 1986 Mar;53(3):331–337. doi: 10.1038/bjc.1986.56. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Wettlaufer J. N., Feiner A. S., Robinson W. A. Vincristine, cisplatin, and bleomycin with surgery in the management of advanced metastatic nonseminomatous testis tumors. Cancer. 1984 Jan 15;53(2):203–209. doi: 10.1002/1097-0142(19840115)53:2<203::aid-cncr2820530203>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  32. Williams S. D., Birch R., Einhorn L. H., Irwin L., Greco F. A., Loehrer P. J. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987 Jun 4;316(23):1435–1440. doi: 10.1056/NEJM198706043162302. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES